Akso Health Group: Form 20-F for the period ended Mar 31, 2026
Filed with the SEC on Jul 23, 2026 and accepted by EDGAR at Jul 23, 2026, 16:05 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2026-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2025-04-01 to 2026-03-31 | $13.8m | us-gaap:Revenues |
| Cost of revenue | 12 months2025-04-01 to 2026-03-31 | $13.8m | us-gaap:CostOfRevenue |
| Gross profit | 12 months2025-04-01 to 2026-03-31 | −$11.3k | us-gaap:GrossProfit |
| Selling, general and administrative | 12 months2025-04-01 to 2026-03-31 | $4.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2025-04-01 to 2026-03-31 | −$20.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2025-04-01 to 2026-03-31 | −$2.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2025-04-01 to 2026-03-31 | −$18.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2025-04-01 to 2026-03-31 | $0.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2025-04-01 to 2026-03-31 | $0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2025-04-01 to 2026-03-31 | 2,168,121,761 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2025-04-01 to 2026-03-31 | −$12.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2025-04-01 to 2026-03-31 | $1.6k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2026-03-31 | $170.6k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2026-03-31 | $189.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2026-03-31 | $189.6m | us-gaap:Assets |
| Current liabilities | At period end2026-03-31 | $8.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2026-03-31 | $8.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2026-03-31 | $180.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-26-080868. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.